In Reply The correspondents raise concerns about the nonrepresentativeness of our sample,1 which arose because we restricted ourselves to publicly available data. Other studies have relied on confidential data that companies agreed to share.2-4 To the best of our knowledge, none of the previous studies on this topic, including that by DiMasi et al,2 which involved only 10 midsized to large companies, are representative.
Wouters OJ, McKee M, Luyten J. Research and Development Costs of New Drugs—Reply. JAMA. 2020;324(5):518. doi:10.1001/jama.2020.8651
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: